Rare Kidney Diseases Market Overview: Major Segments, Strategic Developments, and Leading Companies

The rare kidney diseases market is on the cusp of significant growth, driven by advancements in treatment options and increased focus on personalized care. As research intensifies and new therapies emerge, this sector is attracting considerable attention from both investors and healthcare providers. Let's explore the current market size, leading companies, evolving trends, and key market segments shaping its future.

Projected Market Expansion for Rare Kidney Diseases by 2030
The rare kidney diseases market is expected to surge to a value of $4.88 billion by 2030, growing at a strong compound annual growth rate (CAGR) of 10.2%. Several factors contribute to this rapid expansion, including breakthroughs in genomics-based drug discovery and a rise in orphan drug approvals. Increased investments in rare disease research and the growing adoption of personalized medicine approaches also play a critical role. Furthermore, the development pipeline is expanding with complement and immune-targeted therapies, which are expected to drive market growth. Notable trends in this period include a heightened focus on targeted therapies for rare renal conditions, more clinical trials for orphan kidney drugs, greater use of biologics for immune-related kidney diseases, enhanced companion diagnostic tools for early detection, and increased regulatory support for rare disease drug development.

Download a free sample of the rare kidney diseases market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Players Dominating the Rare Kidney Diseases Market
Several prominent pharmaceutical companies lead the rare kidney diseases market, including Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, and Reata Pharmaceuticals Inc.

A strategic move in this landscape occurred in February 2023 when AstraZeneca Pharmaceuticals LP, a US-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition strengthens AstraZeneca's portfolio in chronic kidney conditions and uncontrolled hypertension. CinCor Pharma, also US-based, specializes in clinical-stage treatments for rare kidney diseases, enhancing AstraZeneca's capabilities in this niche.

View the full rare kidney diseases market report:
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Highlighting Future Directions in Rare Kidney Disease Treatment
Companies in this market increasingly prioritize developing non-immunosuppressive therapies aimed at treating rare kidney diseases. These innovative treatments offer new hope for patients with progressive kidney conditions, where conventional therapies often fall short.

For example, in February 2023, Travere Therapeutics, a US-based biopharmaceutical firm, introduced sparsentan, marketed as Filspari. This drug is the first non-immunosuppressive therapy approved specifically for primary immunoglobulin A nephropathy (IgAN). Filspari works by blocking angiotensin and endothelin receptors, a mechanism different from angiotensin-inhibiting ACE inhibitors and ARBs, which are typically used to manage hypertension and have been repurposed for IgAN due to their kidney blood pressure-lowering effects.

Comprehensive Segmentation of the Global Rare Kidney Diseases Market
The rare kidney diseases market is segmented based on target indications, types of molecules, and routes of administration.

1) Target Indications include IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, and other rare kidney disorders.
2) Molecule Types are divided into small molecules and biologics.
3) Routes of Administration cover oral, intravenous, subcutaneous, and other methods.

Further subsegments detail specific therapies for individual conditions:
- IgA Nephropathy treatments include immunosuppressive therapy and supportive care.
- Lupus Nephritis management involves corticosteroids, antimalarial drugs, and biologics.
- Focal Segmental Glomerular Sclerosis therapies include corticosteroids, angiotensin receptor blockers (ARBs), and other immunosuppressants.
- Membranous Nephropathy care comprises corticosteroids, immunosuppressive agents, and monoclonal antibodies.
- C3 Glomerulopathy treatments focus on complement inhibitors, supportive care, and immunosuppressive therapies.
- Other target indications encompass rare conditions like Alport Syndrome and Thin Basement Membrane Nephropathy.

This detailed classification offers a clear understanding of the specialized treatment options available within the rare kidney diseases market, emphasizing the tailored approaches for each condition.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.